NCT06873191View on ClinicalTrials.gov

A Study to Learn More About Tukysa Once it is Out in the Korean Market

Not yet recruitingOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

December 1, 2026

Primary Completion Date

June 30, 2030

Study Completion Date

June 30, 2030

Conditions
HER2-positive Locally Advanced UnresectableMetastatic Breast Cancer
Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY